Clinical outcomes with fixed-duration therapy (UK real-world data) compared with continuous lenalidomide and low-dose dexamethasone therapy (FIRST trial; MM-020) for transplant-ineligible patients with newly-diagnosed multiple myeloma

Click to increase image sizeClick to decrease image size

Disclosure statement

F.A.S. has received an educational grant and personal travel expenses from Celgene Corporation. F.D. has received grants and honoraria from Celgene Corporation. S.F. and J.K. have no conflicts of interest to disclose. J.A.L. is an employee of Celgene Corporation and holds shares in Celgene Corporation. S.M-S. is an employee of Open Vie. K.R. has received grants and honoraria from Amgen, Celgene Corporation, Janssen, and Takeda and honoraria from AbbVie, Oncopeptides, and Sanofi.

Acknowledgements

The authors would like to thank pH Associates (Sam Oliver and Angela Carter) for their support with data analysis, medical writing services, and assistance, funded by Celgene Corporation. Additional medical writing support was provided by Excerpta Medica (Mauro Locati, PhD), funded by Celgene Corporation, Summit, NJ, USA. The authors are fully responsible for all content and editorial decisions for this manuscript.

Additional information

Funding

Celgene Corporation provided FIRST trial data and funded this research.